RaGuS Trial by Postoperative Patients

• Status: Not yet recruiting
• Trial end date: 2021-09-14
• Target enrollment: 0
• Participant gender: All

Summary

Vasoplegic syndrome is characterized clinically by reduced systemic vascular resistance and normal or increased cardiac output. It is principally observed in cardiovascular and orthopedic interventions and is characterized by a systemic inflammatory response with the inability of the vascular endothelial muscles to contract and a resistance to the action of vasoactive drugs. This event extends the length of stay in the critical care area due to the need of vasoactive drugs.

The investigators aim to assess the standardized application of midodrine in postoperative patients without sepsis and need of vasoactive drugs in order to reduce the length of stay in critical care area and for extension in hospital.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bürgerspital Solothurn
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• Over 18 years of age

• Need of vasoactive drugs after three hours from arrival and adequate volume recovery.

Exclusion Criteria:

• Signs of infection (anamnesis or pro-calcitonin > 0.2 with leukocytosis, CRP and/or fever)

• Serum lactate > 2mmol/l

• Mechanical ventilation

• Therapeutic restrictions or comfort measures at arrival

• "de novo" or acute on chronic heart failure (Reduction of known ejection fraction for more than 20 percent, signs of acute lung edema)

• Pregnant

• Patients with digoxin treatment or history of glaucoma.

• History of midodrine allergy, pheochromocytoma, thyrotoxicosis, tachyarrhythmias or ventricular fibrillation.